| 37683911 | The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF. | J Card Fail | 2024 |
| 37806488 | The HFSA Advanced Heart Failure and Transplant Cardiology Fellowship Consensus Conference. | J Card Fail | 2024 |
| 38069997 | Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper. | JACC Heart Fail | 2024 |
| 37990754 | Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS-986231). | Eur J Heart Fail | 2024 |
| 36114655 | Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction. | Eur J Heart Fail | 2023 |
| 37709385 | HFSA Government Affairs: Advocating for Our Members, Patients and Society. | J Card Fail | 2023 |
| 37797885 | Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. | J Card Fail | 2023 |
| 37889197 | Acute Heart Failure Is a Malignant Process: But We Can Induce Remission. | J Am Heart Assoc | 2023 |
| 37831045 | Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial. | JACC Heart Fail | 2023 |
| 37540060 | Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE. | Eur J Heart Fail | 2023 |
| 37461163 | Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. | Eur J Heart Fail | 2023 |
| 37059514 | Nurturing the Future of Heart Failure: The HFSA Advanced Heart Failure and Transplant Cardiology Task Force. | J Card Fail | 2023 |
| 37117140 | Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. | J Card Fail | 2023 |
| 37038330 | The win ratio method in heart failure trials: lessons learnt from EMPULSE. | Eur J Heart Fail | 2023 |
| 37098791 | Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. | Eur J Heart Fail | 2023 |
| 37462255 | Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure. | Eur J Heart Fail | 2023 |
| 36656377 | Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure. | Clin Res Cardiol | 2023 |
| 36881400 | Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. | JACC Heart Fail | 2023 |
| 36881396 | Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF. | JACC Heart Fail | 2023 |
| 36915227 | Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial. | Eur J Heart Fail | 2023 |
| 36610557 | A Roadmap to Reinvigorating Training Pathways Focused on the Care of Patients With Heart Failure: Shifting From Failure to Function. | J Card Fail | 2023 |
| 36639130 | Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. | Eur Heart J Cardiovasc Pharmacother | 2023 |
| 36597719 | Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial. | Eur J Heart Fail | 2023 |
| 36254693 | Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. | Eur Heart J | 2023 |
| 34786794 | Worsening renal function in acute heart failure in the context of diuretic response. | Eur J Heart Fail | 2022 |
| 35377706 | Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. | Circulation | 2022 |
| 35530511 | Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. | Front Physiol | 2022 |
| 35852527 | Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. | JAMA | 2022 |
| 36521968 | HFSA: Serving Those Who Serve Heart Failure Patients. | J Card Fail | 2022 |
| 36456063 | Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel. | JACC Heart Fail | 2022 |
| 36073112 | Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. | Eur J Heart Fail | 2022 |
| 35933224 | Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies). | Am J Cardiol | 2022 |
| 36066557 | Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. | Eur J Heart Fail | 2022 |
| 35319725 | Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. | JAMA Cardiol | 2022 |
| 35184572 | Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. | Circ Heart Fail | 2022 |
| 35000432 | Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. | Circ Heart Fail | 2022 |
| 35115106 | Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. | J Am Coll Cardiol | 2022 |
| 35236099 | Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. | Circ Heart Fail | 2022 |
| 35228754 | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. | Nat Med | 2022 |
| 34643642 | Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. | JAMA Cardiol | 2022 |
| 32939666 | Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. | Heart Fail Rev | 2021 |
| 33826209 | The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). | Eur J Heart Fail | 2021 |
| 33620131 | Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. | Eur J Heart Fail | 2021 |
| 33590579 | The significance of left ventricular ejection time in heart failure with reduced ejection fraction. | Eur J Heart Fail | 2021 |
| 33728762 | Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. | Eur J Heart Fail | 2021 |
| 33530705 | Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure: A Review of Published Clinical Trials. | Circ Heart Fail | 2021 |
| 33663906 | Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. | J Card Fail | 2021 |
| 33609072 | Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. | Eur J Heart Fail | 2021 |
| 33497808 | The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. | J Card Fail | 2021 |
| 33605000 | Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. | Eur J Heart Fail | 2021 |